Corporate GovernanceMay 12, 2026, 04:03 PM
Pacira Urges Vote for Nominees, Criticizes DOMA Candidates
AI Summary
Pacira BioSciences sent a letter to stockholders ahead of its 2026 Annual Meeting, urging them to vote for its three highly qualified director nominees: Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans. The company highlighted its nominees' extensive experience in healthcare and biopharmaceuticals, crucial for overseeing its 5x30 strategy. Pacira strongly criticized DOMA Perpetual Capital Management LLC's director candidates as underqualified and their proposed plan as misguided, potentially leading to value destruction. The company recommends using the BLUE proxy card and disregarding any white proxy card from DOMA.
Key Highlights
- Pacira urges stockholders to vote "FOR" its three highly qualified director nominees.
- Nominees Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans bring extensive industry experience.
- Pacira criticizes DOMA's director candidates as underqualified and lacking biopharmaceutical expertise.
- DOMA's proposed plan includes broad cost cuts, pipeline discontinuation, and an immediate company sale.
- Pacira emphasizes its focused "5x30 strategy" for sustainable growth and value creation.
- The 2026 Annual Meeting of Stockholders is scheduled for June 9, 2026.
Price Impact
More from PCRX